Aurobindo Pharma shares rise 2% on USFDA nod for nasal spray The pharma company has received approval to manufacture and market Mometasone Furoate Monohydrate Nasal Spray 50 mcg, which will be launched in Q1 FY25. By Chitranjan Kumar
